Retatrutide Vs Ozempic: Next-generation Jab Doubles Weight Loss In Trial
In the first head-to-head Phase 3 trial, Eli Lilly's “retatrutide” cut weight by up to 21% compared with about 9% on Ozempic
News18Oct 31, 2026
Read full articleLatest News
Rs 1,000 cr in 2 stocks: Ashish Kacholia’s big plays on weight loss and AI
One stock has sat in Ashish Kacholia's portfolio since 2018 and now makes injector pens for generic semaglutide, the molecule behind Ozempic. The other came to him before its IPO, more than quadrupled within three weeks of listing and has since given up a third. Together, they account for roughly a third of his disclosed portfolio.
The Financial ExpressOct 31, 2026
Read full article
The Hidden GLP-1 Side Effects No One Talks About
Real users share surprising GLP-1 side effects beyond weight loss — from emotional changes to physical impacts you didn't expect.
BuzzFeedOct 29, 2026
Read full article
Better Than Ozempic? Retatrutide Delivers Double Ozempic's Weight Loss In Phase 3 Trial
Eli Lilly's experimental drug retatrutide produced up to 20.9% weight loss versus 9.4% with Ozempic 2 mg in adults with type 2 diabetes over 80 weeks. Experts say the results are promising, but longer-term safety data and comparisons with Mounjaro are needed.
NDTV.comOct 29, 2026
Read full article
Experimental Lilly drug tops Ozempic in weight loss study
A new late-stage study suggests Eli Lilly’s experimental weekly injection retatrutide may help adults with Type 2 diabetes lose more weight than Ozempic.
WJLAOct 28, 2026
Read full article
Experimental Lilly drug tops Ozempic in weight loss study
A new late-stage study suggests Eli Lilly’s experimental weekly injection retatrutide may help adults with Type 2 diabetes lose more weight than Ozempic.
Baltimore NewsOct 28, 2026
Read full article
GLP-1 microdosing: Can smaller doses help you lose weight without the side effects?
Reddit users are sharing experiences of taking smaller GLP-1 doses for weight loss. Doctors warn that the practice lacks standard protocols, robust evidence and long-term safety data.
India TodayOct 25, 2026
Read full article
Pharmacist shares 'rare condition' affecting some people taking Mounjaro or Wegovy
An expert has highlighted a rare brain disorder that has been reported in people taking GLP-1 injections
Irish MirrorOct 22, 2026
Read full article
Pharmacist 'rare condition' alert for anyone taking Mounjaro Wegovy or Ozempic
Confusion, balance problems and unusual eye movements can signal a rare brain disorder, the expert warned
Cambridge Evening NewsOct 22, 2026
Read full articlePharmacist 'rare condition' alert for anyone taking Mounjaro Wegovy or Ozempic
Confusion, balance problems and unusual eye movements can signal a rare brain disorder, the expert warned
Daily PostOct 22, 2026
Read full article